Latest Hepatitis C and HIV co-infection Stories
-- New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients -- In Phase 3 clinical trials, HOLKIRA
SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- Aethlon Medical, Inc.
- Major regulatory milestone achieved toward approval in the European Union NORTH CHICAGO, Ill., Nov.
- Results demonstrated high response rates in adult chronic hepatitis C genotype 4 patients without cirrhosis BOSTON, Nov.
Treatment of HIV patients co-infected with the hepatitis C virus (HCV) with an anti-retroviral drug therapy not only tackles HIV, but also reduces HCV replication.
HIV-infected patients also infected with hepatitis C virus (HCV) who received a combination of the medications sofosbuvir plus ribavirin had high rates of sustained HCV virologic response 12 weeks after cessation of therapy.
Unprecedented Growth Will be Fuelled by Rapid Uptake of All-Oral, Interferon-Free Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., July 15, 2014 /PRNewswire/
- Results Confirm Efficacy and Safety of an All-Oral combination of Mogrovir(TM) with Ribavirin(TM) in Genotype 1, Therapy Naive HCV Patients. LOS ANGELES, July 1, 2014 /PRNewswire/
Arrival of IFN-Free Therapies Will Bring Patients For Whom Current Therapies are Ineffective Back to the Drug-Treated Population, According to Findings from Decision Resources Group BURLINGTON,
-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) -- Health Canada grants AbbVie's request for Priority Review MONTREAL,
- A volcanic mudflow.